Background -Nearly all available treatments for pulmonary arterial hypertension (PAH) have
Introduction
Pulmonary arterial hypertension (PAH) is a progressive disease leading to right heart failure and death. [1] [2] Seven drugs developed in the last 20 years have been shown to improve six-minutewalk distance (6MWD) in patients with PAH and have been approved for use in the U.S. on that basis. While 6MWD is viewed by regulatory agencies as a clinically important endpoint in its own right, several studies have shown that patients who achieve greater improvements in 6MWD
(or reach certain absolute values of 6MWD) have better clinical outcomes. [3] [4] [5] However, such observational data are insufficient to determine whether 6MWD is a valid surrogate endpoint for clinical events. [6] [7] [8] [9] Determining the validity of 6MWD as a surrogate endpoint in PAH trials is particularly timely in light of conflicting results of recent meta-analyses. [10] [11] [12] [13] While some of these contradictions may be due to inadequate sample size or follow-up, or to intrinsic limitations of study-level meta-analyses, these differences also suggest the possibility that 6WMD is a poor surrogate. In this study, we used two complementary approaches to validate 6MWD. [14] [15] [16] [17] First,
we used patient-level data from all available Phase III randomized clinical trials submitted for drug approval to assess whether changes in 6MWD ( 6MWD) mediate the relationship between treatment assignment and clinical outcomes. Second, we quantified how treatment effects on 6MWD predicted treatment effects on patient-centered outcomes, with the goal of determining whether a threshold 6MWD exists beyond which investigators could reliably predict that superior clinical outcomes would follow in future trials.
Methods

Study Population
Through a contract with the U.S. Food and Drug Administration (FDA) to one author (SDH), we
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Additional trial details are available elsewhere. [18] [19] [20] [21] [22] [23] [24] [25] We purposely included trials of treatments that were not approved by the FDA (e.g., sitaxsentan), a result of either unacceptable toxicity of effective dosages or dosages that were determined to be ineffective. Both the mediator and threshold analyses would be predictably biased if we only included FDA-approved treatments, and the resulting conclusions would not be useful for future trial design or regulatory decisions.
All included trials reported similar methodology, including outcome assessment and variable collection at 12-weeks follow-up.
Clinical events
Clinical events included any of the following before the end of the trial: death, lung transplantation, atrial septostomy, hospitalization due to worsening PAH, withdrawal for worsening right-heart failure, or addition of other PAH medications. We did not consider a deterioration in 6MWD to represent a clinical event because it was the surrogate we were attempting to validate. Further details are provided in the Supplemental Material, Table 1 .
6MWD
Change in 6MWD was calculated as the difference, in meters, between the distance walked at baseline and 12 weeks. Baseline 6MWD was recorded at or within two weeks of randomization.
In all analyses, patients who were missing a 12-week 6WMD because they died during the trial (n=45, 2%) were assigned a value of 0. We chose this value to reflect the fact that deaths are and the resulting conclusions would not be useful for future trial design or regul la at ator r ry de de deci ci cisi si sion on o s. s r
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Mediator Analysis
We utilized standard methodology to determine whether 6MWD mediates the relationship between treatment assignment and the development of clinical events at 12-weeks follow-up. [15] [16] We defined treatment assignment as either active treatment or placebo. We conducted regression analyses to evaluate the four following hypotheses. Rejecting the null for all four hypotheses was necessary to support 6MWD as a mediator/surrogate end point.
(1) Treatment assignment has a significant effect on 6WMD from baseline to 12 weeks;
(2) 6MWD has a significant effect on the odds of developing a clinical event;
(3) Treatment assignment has a significant effect on the odds of developing a clinical event;
(4) The effect of treatment assignment on the odds of developing a clinical event is attenuated when 6MWD is added to the model.
We used logistic or linear regression for binary or continuous outcomes, respectively.
All regression models adjusted for study to account for study-level differences in treatment assignment, and for baseline walk distance to account for patient-level differences in risk of
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After rejecting the null for the above four hypotheses, we determined the proportion of variability explained by the 6MWD in the relationship between treatment assignment and development of a clinical event. [28] [29] We used a generalized linear model with a logit link to quantify the relationship between treatment assignment and log odds of developing a clinical event with adjustment for study and baseline walk ('reduced' model). We then added the 6MWD to the model ('full' model). The subsequent change in the treatment assignment coefficient between the reduced and full models provided the proportion of variability explained by 6MWD. Bootstrap resampling was used to create a confidence interval for the percent change. Estimates of percent change were obtained for each resampled dataset, and the standard deviation of the estimates across 1000 resampled datasets was used as the standard error. 30 In addition, we used a modified Sobel test to assess whether the amount of mediation was statistically significant; the modified test accounted for the fact that the surrogate (continuous) and the outcome (binary) were on different scales. 16, 31 We evaluated the assumption of no effect modification between treatment and the mediator 31 by fitting a logistic regression model for clinical events with an interaction term between treatment assignment and 6MWD.
Threshold Effect Analysis
We then conducted a trial-level meta-analysis and meta-regression to assess the relationship of the treatment effect on the mediator ( 6MWD) with the treatment effect on the odds of developing a clinical event at 12-weeks follow-up. This threshold analysis proceeded in four steps.
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Second, we estimated values for the outcome, the placebo-adjusted study-level log odds of developing a clinical event between baseline and 12-weeks, using logistic regression analyses within each trial. In these trial-specific patient-level regressions, treatment (drug and dose, entered as indicator variables with placebo as the referent) was the exposure, clinical event (yes or no) was the outcome, and adjustment was made for baseline 6MWD. Exact logistic regression was used when the number of clinical events in a study was small.
Third, we used the 21 drug/dose combinations vs. placebo across trials in a fixed-effects meta-regression relating estimated difference in 6MWD to the estimated log odds ratio for clinical events. The square of the inverse standard error was used as a weight to account for uncertainty in the estimated log odds ratio. We determined the threshold effect by calculating 95% prediction bands around the meta-regression line. The threshold was calculated as the value of difference in 6MWD where the upper prediction band crossed the null value of 1.0 for relative odds of a clinical event. Prediction bands quantify the uncertainty in predicting the difference in clinical worsening in a single trial given a defined difference in 6MWD. Linearity of the final regression model was assessed via standard regression diagnostics.
Finally, we sought to determine whether study-level patient characteristics confounded the association between 6MWD and relative odds of clinical events. Potential confounders were chosen a priori based on known differences in treatment response by race and sex, 32 and by diagnosis and NYHA functional classification. 33 Therefore, covariates in our regression model egression was used when the number of clinical events in a study was small.
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We conducted two secondary analyses. First, we excluded the PHIRST study, in which patients were permitted to use background therapy with other approved PAH-specific agents.
Second, we removed patients who were New York Heart Association (NYHA) class IV at randomization since it is unlikely that these patients will be included in future clinical trials. All regressions and meta-regressions were conducted in R version 2.13 (R Development Core Team, Vienna, Austria).
This study was determined to be exempt by the Institutional Review Board of the University of Pennsylvania (approval #814001). All co-authors had access to the study data, take responsibility for the analysis, and had authority over manuscript preparation and the decision to submit for publication.
Results
The ten trials included 2404 patients; 1563 (65%) were allocated to active treatment.
Participants' median age was 50 years (range: 10 to 90 years), 22% were male, and 5% were black ( Table 1) . Five hundred eighty one patients (25%) had a diagnosis of PAH due to connective tissue disease and 1349 (57%) were categorized as NYHA classification III or IV.
Forty-five patients (2%) died between baseline and 12-weeks follow-up. An additional 153 patients (6%) experienced other clinical events; 83 of these did not have 12-week walk distance.
Mean baseline walk distance was 341 m (standard deviation: 85.7 m). Demographic, anthropometric, laboratory, and hemodynamic values were similar between groups defined by treatment allocation.
This study was determined to be exempt by the Institutional Review Boar ar rd d o of o t the he he University of Pennsylvania (approval #814001). All co-authors had access to the study data, a ake ke e r r res es espo po ons ns n ib ibilit it ty y y fo f r the analysis, and had auth h hor o o i it ty over manusc sc cript pt p p pr re reparation and the d de deci ci isi s on to su ubm bm mit t f for or pub ub ubli li lica ca cat ti tion on. . .
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Characteristics of the ten trials are presented in Table 2 . Study-level percentages of female patients and patients diagnosed with CTD-related PAH were consistent across studies.
Percentages for NYHA classification III/IV and black race showed more variation across studies.
Does 6MWD mediate the relationship between treatment assignment and clinical events?
The four criteria necessary to establish 6MWD as a mediator of the relationship between treatment assignment and development of a clinical event are listed in Table 3 . For each, we found a statistically significant result in the required direction. First, assignment to active treatment vs. placebo led to greater differences in the 6MWD (mean difference in 6MWD: 
Does a threshold effect exist for 6MWD?
Compared with placebo, nearly all drug/dose combinations resulted in a greater 6MWD at 12-weeks follow-up ( Table 4 In a sensitivity analysis, we removed the four drug/dose combinations fro o om m th the e e PH PH PHIR IR IRST ST f f tudy, as this study was the only one to allow concomitant background therapy. Excluding this t tud ud udy y y re resu ult lt lted ed d in n a a a sm s aller threshold value of 25. 5.7 7 7 m m m for the differ er ren e ce ce i i in n n 6MWD. In an ad dd di diti t onal ana aly lys s sis s s, r re em mov ovin ing g N NY NYH H HA A A cl cla ass IV IV IV pat t tie e ents s s (n (n (n= =1 =12 27 27) ) di did d no ot t t a ap ppr pr re ec cia iabl bl ly y y ch chan an ange ge e esu su ult lt lts. s. s Fu Fu Furt rt rth he her r r de de eta ta tail il ils s ar ar are e pr r rov ov o id id ided ed ed i in n n th th the e e Su Su Supp pp ppl le lem me ment nt n al al al M M Mat at ater er ria ial l l. . rate over 12 weeks.
We found that only 4 of the 21 drug-dose combinations produced effects on 6MWD that could be said, with conventional degrees of certainty, to be associated with clinical improvements (Figure 1) . If the lower threshold value of 25.7 m is used, then 5 of the remaining 17 drug-dose combinations would be considered to produce statistically significant effects on clinical outcomes in the absence of background therapy. Of these 9 total drug-dose combinations that met the lower threshold value, one involved a drug that is not approved by the FDA (sitaxsentan) and two involve dosages that are not included in FDA labeling (sildenafil 40 mg TID and sildenafil 80 mg TID). Three drugs (iloprost, tadalafil, and treprostinil) did not meet either of the threshold values.
It is essential to explore the validity of surrogate endpoints because valid surrogates provide efficient mechanisms for early phase studies of new interventions. Specifically, trials utilizing validated surrogate endpoints can be conducted more quickly, with smaller sample sizes, fewer risks to subjects, and reduced research costs than trials that use true clinical endpoints. [34] [35] However, only if surrogate endpoints are validated will they clearly provide these virtues; in the absence of validation, there is considerable risk, as shown famously in the CAST trial, 36 of falsely concluding the effectiveness of a new intervention.
Our data also add to a growing literature on the use of 6MWD as an outcome measure in other settings. Using different methods, 6MWD has been evaluated in idiopathic pulmonary fibrosis, 37 chronic obstructive pulmonary disease, 38 and cardiac rehabilitation. 39 In our study, we found that the proportion of the effect of treatment on preventing clinical events explained by the change in 6MWD was 22.1%, which falls well below the 50-75% threshold for a valid surrogate described by Freedman, 28 although some consider this an overly stringent criterion. 15 Clearly, either of the threshold values.
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The threshold value we identified of 41.8 meters for the difference in 6MWD may be considered for use as the level of improvement in 6MWD necessary to reliably conclude that the intervention will confer clinical benefits in future trials. Using different methods and patients from a single study (the SUPER study), Gilbert et al. estimated a minimally clinically important difference of 41 m that correlated with patient-reported improvement. 41 Similarly, in untreated PAH patients, Paciocco et al. found that each increase in 50 m walked was associated with an 18% reduction in mortality. 42 The consistency of findings across these studies using different methods supports the robustness of this result. However, 6MWD remains an inadequate surrogate endpoint given the modest degree of mediation of the treatment effect.
Confidence in our results stems from the large sample size employed and the fact that the treatment effects on changes in 6MWD and on clinical events were consistent across all drug doses. 43 Nonetheless, this study has limitations. First, as with any meta-analysis, the findings are subject to errors in the conduct, data entry, or analysis of the primary data. Second, these primary trials included mostly women and whites, and used relatively short follow-up periods. We are unable to evaluate clinical endpoints that occur after 12 weeks and our results should not be generalized beyond this time period. However, the demographics represented are consistent with the broader epidemiology of PAH, and the included trials all provided similar follow-up, clinical event definitions, and outcome measurement, making them well suited for our meta-analytic approach.
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All of the trials that we examined were placebo-controlled, which is an additional strength. However, one allowed concomitant background therapy. Removal of the PHIRST trial reduced our threshold value, suggesting that future trials employing background therapies may be subject to larger threshold values than those reported here. In other words, in the presence of an effective PAH therapy, an RCT of a new therapy may need to produce larger differences in the 6MWD to provide confidence that the results correspond to differences in clinical outcomes. We were unable to further explore the role of background therapy due to small sample sizes. Future research, therefore, is needed, particularly in light of ethical questions surrounding the future conduct of placebo-controlled trials in PAH. In conclusion, we used two complementary approaches to examine the validity of 6MWD as a surrogate endpoint in clinical trials of PAH therapies. We were able to identify significant threshold effects of 6MWD that can be used to guide future RCTs, and we found that 6MWD is a mediator in the relationship between treatment and clinical outcome.
However, because 6MWD does not explain a large proportion of this treatment effect, it may not be sufficient to use it as a lone surrogate endpoint. Further studies are needed to identify Finally, we used statistical techniques to help address a clinical question. Wh W W i il le e ou our r r hreshold estimate provides a clear idea of what 6MWD would be needed to indicate that the be ene n nefi fi fits ts of f f a a a t t trea at tm tmen e t will be greater than zero, , t t the he he inference of a a a "cli lini ni ic cally important" d diff f fe erence in ou out tco om ome es s m m mig igh ht ht w war arra ra ran nt se se elect tio on of f f a a a dif if ff fe fere re ent nt t thr hr res sh hol ld d d. I Ind nd ndi iv ivid idua u ual l pa pa atie en ents ts m m may h how ow w c c cli li lini ni nica ca cal l im im mpr pr prov ov ovem em emen en ent wi wi with th t ou ou ut t t re rea ac achi hi hing ng ng a a a c ce er erta ta ain in i 6M 6M 6MWD WD WD t t thr hr hres e esh ho hold ld d v val al alue ue ue a a and nd nd p p pa at atie ie ent nt nts s s wh wh who o mprove thei ei ir r 6M 6M 6MWD WD WD m m may ay y n n no ot o n nec ec e es es e sa sa ari ri rily ly y e e exh xh xhi i ibi bi bit t cl cl clin in i ic c cal al al i i imp mp mpro r rove eme me ment nt nt. H H How ow wev ever er e , , th th the combination surrogate endpoints that may have superior characteristics, and to determine if this threshold value we identified applies to trials employing background therapy or not employing placebo controls at all.
3. Provencher S, Sitbon O, Humbert M, Cabrol S, Jais X, Simonneau G. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J. Table 1 . Characteristics of study participants; summaries provided as median (Q1-Q3) unless otherwise indicated by n (%). proportionate to study weights (detailed in Table 4 , and based on inverse variance weighting).
The shaded grey area corresponds to the bounds of the 95% prediction intervals. The threshold value is indicated on the horizontal axis at 41.8 m.
